48 hours with Fiasp. What are my first thoughts on Faster insulin Aspart?
If you follow social media, you’ll be aware that Novo Nordisk’s Faster Insulin Aspart (brand name Fiasp) became available earlier this year, having passed its […]
If you follow social media, you’ll be aware that Novo Nordisk’s Faster Insulin Aspart (brand name Fiasp) became available earlier this year, having passed its […]
As many people (but let’s face it, not all) are aware, the NICE target for Hba1C level is 6.5% as this is the point at […]
Over the past couple of months, I’ve seen this question asked multiple times on many fora. Facebook, email lists and forums have all seen people […]
As you might guess from the title, I’ve noticed some changes in my hypo awareness, and I think I’d say that they’re generally in a […]
The first of the faster insulins that we saw a great deal of detail about at EASD 2016 is due to arrive at wholesalers near […]
Earlier this week I published the first set of results of the survey of CGM and Libre users that I undertook last year. There was […]
The 10th international conference on Advanced Technologies and Treatments for Diabetes (ATTD) has come to a close and once more the twitter feed has been […]
Now that the survey to try and find out what CGM and Libre users thought of the technology and how it had affected their self-management, […]
Late last year, I wrote about form and physicality of the hybrid closed loop, bemoaning the stuff I was carrying, and a few other things. […]
This question seems relatively straightforward to answer. Surely it’s just to provide a way of delivering insulin automatically, leading to less user intervention and making […]
Copyright © 2026 | WordPress Theme by MH Themes